跳至主要内容
临床试验/JPRN-jRCTs031210339
JPRN-jRCTs031210339招募中4 期

Effect of Tofogliflozin on Urine Albumin-to-Creatinine Ratio Compared to Metformin Hydrochloride in Diabetic Kidney Disease - TRUTH-DKD Study

Kuwahara Koichiro0 个研究点目标入组 120 人开始时间: 2021年9月22日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Patients who meet all of the following selection criteria are included.
  • 1. Type 2 diabetic patients
  • 2. Patients aged 20 years or older at the time of obtaining consent
  • 3. Patients with HbA1c 6.5 or more and 9.0% or less within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor/metformin)
  • 4. Patients who have been judged by their doctor to need a diabetic drug when they are first seen, or who have already taken a diabetic drug and have decided that it is necessary to add one diabetic drug.
  • 5. Patients who have been receiving RAS inhibitors (ARB, ARNI, ACE inhibitors, direct renin inhibitors) for 4 weeks or longer
  • 6.Patients with eGFR of 30 or more (mL/ min/1.73m2) within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor/metformin)
  • 7. Patients with urinary albumin/creatinine ratio (UACR) of 30 or more and less than 2000 (mg /gCr) (4 weeks or more without taking SGLT2 inhibitor/metformin) within 13 weeks before obtaining consent Evaluate by inspection value)
  • 8. Patients for whom written consent was obtained based on the patient's free will after receiving sufficient explanation for participation in this study

排除标准

  • 1. Patients receiving treatment with SGLT2 inhibitor or metformin within 13 weeks before obtaining consent
  • 2. Dialysis patient
  • 3. Patients with a history of severe hypoglycemia
  • 4. Patients with hypersensitivity to SGLT2 inhibitor or metformin
  • 5. Pregnant women, lactating patients, and patients who wish to raise children
  • 6. Patients with BMI of 35 kg / m2 or more based on the latest measured values within 13 weeks before obtaining consent
  • 7. Patients who are contraindicated for the study drug
  • 8. Other patients who the attending physician deems inappropriate as a subject

研究者

发起方
Kuwahara Koichiro

相似试验